The leading resource for comprehensive insight and
intelligence on the global psychedelics industry.
Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic healthcare industry.
The industry’s most engaged event series where trusted thought leaders, active investors and top-tier operators
connect and collaborate.
A B2B media platform for the psychedelic science and healthcare industry
'Regulators can see the safety, efficacy and potential of these molecules, and they all seem very open to taking them through clinical trials.’
@SmallPharma's Chief Medical & Scientific Officer, Carol Routledge, spoke to PSYCH on the company's DMT study:
Small Pharma’s Chief Medical and Scientific Officer, Carol Routledge, on DMT’s power to treat Major Depressive Disorder | PSYCH
Small Pharma recently completed a Phase I trial to treat Major Depressive Disorder (MDD), with proprietary DMT formu...
Psychedelic medicines are disrupting the way we approach healthcare, particularly psychiatry.
@TheTripReport1's Founder, @Zach_Haigney, contributed to the 200+ page The Psychedelics as Medicine Report: Third Edition
Download your complimentary copy today https://psych.global/report
The Psychedelics as Medicine Report: Third Edition is out now.
The publication provides unsurpassed market insights and intelligence, empowering investors, operators and regulators to make informed decisions.
Download your complimentary copy today:
'Using VR to obtain non-ordinary states will greatly increase the availability of these types of experiences.'
aNUma's Chief Science Officer, Joe Hardy, was joined by @TRIPPVR's CEO, @Nanea, to discuss the technology at last week's PSYCH Investor Summit: https://youtu.be/aI0WWIPIHTQ
'The symptoms of depression, burnout and moral injury call out for research that looks at whether psychedelics can play a role in healing the healers'.
@TIME explored the link between psychedelic medicines, COVID-19 and the health of healthcare workers:
COVID-19 Opened Door to a New Era in Psychedelic Medicine
We need to invest in studying psychedelic treatments ‘further and faster’
Scientists have been researching psychedelics for decades.
Early research indicated that psychedelics were useful in treating alcoholism, anxiety, depression and aiding the dying.
@michaelpollan discuss what's next:
Michael Pollan on the Ebbing Drug War and the Fast-Growing Era of Psychedelic Research - MindSite News
For three decades, in eight books and untold articles, Michael Pollan has been writing and teaching us about the ...
Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.
Gain unparalleled market intelligence and insights from thought-leaders and industry experts, identifying lucrative opportunities for investors, operators and regulators.